UK's latest Budget increases R&D investment and tax credit

11 March 2020
parliament_li

Presenting his first Budget today, Britain’s Chancellor of the Exchequer Rishi Sunak announced that research and development investment will be increased by £22 billion ($28.6 billion), making it the fastest and biggest R&D ever R&D spend.

Overall, the Office for Budget Responsibility (OBR) has said that the Budget was “largest giveaway since 1992” and it will add more than £100 billion to public debt by 2024.

Mr Sunak also announced increased tax relief for companies that carry out qualifying R&D, a measure that increases the rate of the R&D expenditure credit from 12% to 13%, which is expected to affect 7,000 firms, will cost £1.2 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical